Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Werewolf Therapeutics (HOWL) Operating Expenses (2021 - 2025)

Werewolf Therapeutics (HOWL) has disclosed Operating Expenses for 5 consecutive years, with $15.7 million as the latest value for Q3 2025.

  • On a quarterly basis, Operating Expenses fell 8.16% to $15.7 million in Q3 2025 year-over-year; TTM through Sep 2025 was $71.6 million, a 2.89% increase, with the full-year FY2024 number at $75.5 million, up 24.87% from a year prior.
  • Operating Expenses was $15.7 million for Q3 2025 at Werewolf Therapeutics, down from $17.5 million in the prior quarter.
  • In the past five years, Operating Expenses ranged from a high of $20.5 million in Q4 2022 to a low of $7.5 million in Q1 2021.
  • A 5-year average of $16.3 million and a median of $17.1 million in 2024 define the central range for Operating Expenses.
  • Peak YoY movement for Operating Expenses: soared 106.2% in 2022, then dropped 29.32% in 2023.
  • Werewolf Therapeutics' Operating Expenses stood at $17.9 million in 2021, then increased by 14.42% to $20.5 million in 2022, then decreased by 29.32% to $14.5 million in 2023, then soared by 40.69% to $20.3 million in 2024, then dropped by 22.71% to $15.7 million in 2025.
  • Per Business Quant, the three most recent readings for HOWL's Operating Expenses are $15.7 million (Q3 2025), $17.5 million (Q2 2025), and $18.0 million (Q1 2025).